Innovative Multimodal Imaging Techniques in Brain Tumor Clinical Trials
|
|
|
- Coleen Sherman
- 5 years ago
- Views:
Transcription
1 Innovative Multimodal Imaging Techniques in Brain Tumor Clinical Trials Benjamin M. Ellingson, Ph.D. Assistant Professor of Radiology, Biomedical Physics, and Bioengineering Brain Tumor Imaging Laboratory (BTIL) Dept. of Radiological Sciences David Geffen School of Medicine at UCLA CTSI: Neuroimaging: A Short Course on Modern Imaging Modalities in Clinical Invest. 12 April 2013
2 Basics of Brain Tumor Biology
3 Brain Tumor Biology Mutations can cause protein structure alterations, resulting in a cascade of molecular changes (signaling) These can cause further issues and downstream effects Uncontrolled Proliferation Metastases Metabolic Dysfunction
4 Brain Tumor Biology Cancer arises from normal cells Benign Non-cancerous tumor. Slow growing. Can transform to a malignant tumor Malignant Cancerous. Invades and destroys nearby tissue and infiltrates/metastasizes
5 Brain Tumor Biology Clonal Genetic Model of Cancer Fienberg, Nature Genetics, 2006
6 Brain Tumor Biology WHO = World Health Organization Grade: How abnormal cells look under the microscope How quickly they are likely to grow or spread I-IV from least to most malignant/differentiated I: Well differentiated (low Grade) II: Moderately differentiated (Intermediate Grade) III: Poorly differentiated (High Grade / Malignant) IV: Undifferentiated (High Grade / Malignant)
7 Brain Cancer - Gliomas Brain Cancer Does Not Metastasize** (No Staging, Only Grading) Neuroblastomas & Epidemoma Oligodendrogliomas Oligodendroglioma (WHO II) Anaplastic Oligodendroglioma (WHO III) Astrocytomas Astrocytoma (WHO II) Anaplastic Astrocytoma (WHO III) Mixed Gliomas Astrocytoma and Oligodendroglioma Glioblastoma (GBM) - WHO IV
8 Brain Cancer Incidence Central Brain Tumor Registry United States, 2012
9 Brain Cancer Histology Hayden, Nature, 2010
10 Cancer Phenotypes Key Phenotypes/Characteristics of Glioblastoma Uncontrolled Proliferation (positive feedback)
11 Cancer Phenotypes Key Phenotypes/Characteristics of Glioblastoma Uncontrolled Proliferation (positive feedback) Hypoxia (HIF-1α) Invasion - Migration
12 Cancer Phenotypes Key Phenotypes/Characteristics of Glioblastoma Uncontrolled Proliferation (positive feedback) Hypoxia (HIF-1α) Invasion - Migration Vascular Proliferation - Angiogenesis
13 Cancer Phenotypes Key Phenotypes/Characteristics of Glioblastoma Uncontrolled Proliferation (positive feedback) Hypoxia (HIF-1α) Invasion - Migration Vascular Proliferation - Angiogenesis Excretion of Growth Factors and Signaling Molecules
14 Cancer Phenotypes Key Phenotypes/Characteristics of Glioblastoma Uncontrolled Proliferation (positive feedback) Hypoxia (HIF-1α) Invasion - Migration Vascular Proliferation - Angiogenesis Excretion of Growth Factors and Signaling Molecules GOAL: Detect & Quantify these Phenotypes/Behaviors
15 Biomarkers Definition of Biomarkers A characteristic that is objectively measured and evaluated as an indicator of normal biological processes, pathogenic processes, or pharmacologic responses to a therapeutic intervention Mutation Genome/Prote ome Signal Pathway Phenotype/Clinical Characteristic Imaging Characteristic Outcomes
16 Biomarkers Definition of Biomarkers A characteristic that is objectively measured and evaluated as an indicator of normal biological processes, pathogenic processes, or pharmacologic responses to a therapeutic intervention Mutation Genome/Prote ome Signal Pathway Phenotype/Clinical Characteristic Imaging Characteristic Outcomes
17 Current Therapies for Brain Tumors Surgical Resection Extent of Resection (biopsy vs. resection) affects OS High grade gliomas: GTR 2-yr survival 19%, STR = 0% (Ammirati, Neurosurg, 1987) OS GTR = 13 mo vs. STR = 8.8 mo (Lacroix, J Neurosurg, 2001) OS GTR = 14 mo vs. STR = 11 mo (Sanai, Neurosurg, 2008; Fadul, Neurology, 1988) High Grade Gliomas cannot be cured with surgery Goal is to diagnose, relieve mass effect, and achieve GTR (Ryken, J Neuroonc, 2008)
18 Current Therapies for Brain Tumors Radiation Therapy External Beam Radiation Therapy (XRT) significantly prolongs survival Surgery Alone ~ 3-4 mo OS; Surgery + RT ~ 7-12 mo OS (Buatti, J Neuroonc, 2008; Stupp, N Eng J Med, 2005; Walker, J Neurosurg, 1978) Dose 4500 cgy ~ 13 week OS; 6000 cgy ~ 42 week OS Administered 5 days per week in Gy Fractions Interstitial Brachytherapy Implantation of radioactive seeds Limited value and rarely used -- results in substantial radiation necrosis Experimental RT Proton beam therapy; Neutron Capture Therapy Radiosensizers
19 Current Therapies for Brain Tumors Chemotherapy (Anti-neoplastic Agents) Adjuvant chemo >6-10% increase in 1 year survival rates (Fine, Cancer, 1993; Stewart, Lancet, 2002) Temozolomide (TMZ) -- * Current standard of care Orally active alkylating agent approved by FDA in 2005 RT+TMZ followed by adj TMZ significantly improves OS (Stupp, N Eng J Med, 2005) PFS 6.9 mo vs 5 mo; OS 14.6 mo vs mo; 2 yr survival rate 26% vs 10%
20 Current Therapies for Brain Tumors Chemotherapy (Anti-neoplastic Agents) Nitrosoureas: (BCNU; carmustine & carmustine wafers [Gliodel]) Approved by FDA in 2002 Increased survival 13.8 mo vs mo (Westphal, Acta Neurochir, 2006) Lots of toxicity & other issues (CSF leaks, increased ICP) UT Houston Medical Center
21 Current Therapies for Brain Tumors Other Chemotherapy (Anti-neoplastic Agents) Lomustine (CCNU) Alkylating agent 5-FU Transformed into different cytotoxic metabolites, resulting an apoptosis Vorinostat Histone deacetylase inhibitor Irinotecan (Camptosar) topoisomerase inhibitor -- prevents DNA from unwinding Topotecan (Hycamtin) topoisomerase inhibitor Vincristine (Oncovin) leurocristine (VCR) - vinca alkaloid -- mitotic inhibitor Temsirolimus (Torisel) Cytotoxic mtor inhibitor - blocks growth and division Anti-Proliferative Anti-Mitotic UT Houston Medical Center
22 Current Therapies for Brain Tumors Anti-Angiogenic Agents (Reduces Blood Vessels) Bevacizumab (Avastin) -- VEGF Humanized monoclonal antibody that inhibits VEGF-A. FDA Approval for recurrent GBM in May 2009 Increases 6 month PFS (Vrendenburgh, Clin Cancer Res, 2007; J Clin Onc, 2007) Cediranib (AZD2171) Tyrosine kinase inhibitor, VEGF inhibitor Sorafenib Tyrosine kinase inhibitor, VEGF inhibitor Cetuximab EGFR inhibitor Erlotinib Tyrosine kinase inhibitor, EGFR UT Houston Medical Center
23 Current Therapies for Brain Tumors Immunotherapy Dendritic Cell Vaccine Creates a vaccine from patient-specific tumor cell proteins + dendritic cells from the patients blood. Dendritic cells mediate T-cell immune response to the remaining tumor Rindopepimut (CDX-110) Immunotherapy that targets tumor specific oncogene EGFRvIII Retroviral Vectors (Toca511) Retrovirus that delivers genetic instructions to produce cytosine deaminase inside cancer cells. CD then converts 5-FC (an antifungal) to 5-FU (cytotoxic) Alloreactive Cytotoxic T Lymphocytes (AlloCTL) UT Houston Medical Center
24 Current Therapies for Brain Tumors Phenotype/Clinical Characteristic Imaging Outcomes UT Houston Medical Center
25 Advanced Neuroimaging Protocol for Clinical Trials Magnetic Resonance Imaging (MRI) Standard MR Techniques T2/FLAIR Edema Non-enhancing (infiltrating) tumor T2 Relaxometry Edema Diffusion MRI Cellularity, Proliferation, Invasion Dynamic Contrast-Enhanced (DCE) MRI Vascular Permeability Dynamic Susceptibility-Contrast (DSC) MRI Blood Volume, Blood Flow Contrast-Enhanced T1-Weighted Abnormal Vasculature Proliferative Tumor
26 Advanced Neuroimaging Protocol for Clinical Trials Positron Emission Tomography (PET) 18 F-FDG PET Glucose Metabolism 18 F-FLT PET DNA Synthesis / Proliferation 18 F-FDOPA PET Amino Acid Uptake/Transport/Metabolism
27 Advanced Neuroimaging Protocol for Clinical Trials Magnetic Resonance Imaging (MRI) Standard MR Techniques T2/FLAIR Edema Non-enhancing (infiltrating) tumor T2 Relaxometry Edema Diffusion MRI Cellularity, Proliferation, Invasion Dynamic Contrast-Enhanced (DCE) MRI Vascular Permeability Dynamic Susceptibility-Contrast (DSC) MRI Blood Volume, Blood Flow Contrast-Enhanced T1-Weighted Abnormal Vasculature Proliferative Tumor
28 Standard MRI - T2/FLAIR/Relaxometry Mobile H2O Immobile H2O Long T2 (Bright) Short T2 (Dark)
29 Standard MRI - T2/FLAIR/Relaxometry T2-Weighted Edema
30 Standard MRI - T2/FLAIR/Relaxometry T2-Weighted Infiltrative Tumor
31 Standard MRI - T2/FLAIR/Relaxometry T2-Weighted FLAIR
32 Standard MRI - T2/FLAIR/Relaxometry T2 FLAIR Double IR
33 Advanced Neuroimaging Protocol for Clinical Trials Magnetic Resonance Imaging (MRI) Standard MR Techniques T2/FLAIR Edema Non-enhancing (infiltrating) tumor T2 Relaxometry Edema Diffusion MRI Cellularity, Proliferation, Invasion Dynamic Contrast-Enhanced (DCE) MRI Vascular Permeability Dynamic Susceptibility-Contrast (DSC) MRI Blood Volume, Blood Flow Contrast-Enhanced T1-Weighted Abnormal Vasculature Proliferative Tumor
34 Standard MRI - T2/FLAIR/Relaxometry
35 Differential Quantitative T2 Mapping (DQT2) Ellingson, J Neuroonc, 2012
36 Differential Quantitative T2 Mapping (DQT2) Pre-Bev Post-Bev Pre-Bev Post-Bev Ellingson, J Neuroonc, 2012
37 Differential Quantitative T2 Mapping (DQT2) Ellingson, J Neuroonc, 2012
38 Advanced Neuroimaging Protocol for Clinical Trials Magnetic Resonance Imaging (MRI) Standard MR Techniques T2/FLAIR Edema Non-enhancing (infiltrating) tumor T2 Relaxometry Edema Diffusion MRI Cellularity, Proliferation, Invasion Dynamic Contrast-Enhanced (DCE) MRI Vascular Permeability Dynamic Susceptibility-Contrast (DSC) MRI Blood Volume, Blood Flow Contrast-Enhanced T1-Weighted Abnormal Vasculature Proliferative Tumor
39 Diffusion MRI Ellingson et al., Concepts in MR, 2008
40 Diffusion MRI
41 Diffusion MRI is a Cellularity Biomarker Ellingson & Cohen-Adad, Chpt. 3.1: Diffusion-Weighted Imaging in Quantitative Biomarkers of the Spinal Cord, Elsevier Press, 2013 Ellingson, JMRI, 2010
42 Diffusion MRI is a Cellularity Biomarker ADC Map Edema Necrosis Viable Tumor (Dark)
43 Diffusion MRI is a Cellularity Biomarker
44 Diffusion MRI is a Cellularity Biomarker ADC Before RT ADC After RT
45 Diffusion MRI is a Cellularity Biomarker Functional Diffusion Mapping (fdms)
46 Diffusion MRI is a Cellularity Biomarker Pre-Tx FLAIR Post-Tx FLAIR Pre-Tx T1+C Post-Tx T1+C fdm PFS = 247 Days OS = 247 Days PFS = 258 Days OS = 662 Days PFS = 438 Days OS = 1613 Days Ellingson, Neuro Onc, 2012
47 Diffusion MRI is a Cellularity Biomarker Ellingson, Neuro Onc, 2012
48 Cell Invasion, Motility, and Proliferation Level Estimate (CIMPLE ) Maps Proliferation Invasion Ellingson, Magn Reson Med, 2011
49 Cell Invasion, Motility, and Proliferation Level Estimate (CIMPLE ) Maps T1+C Proliferation 0 Cell Proliferation [1/yr] 10 Ellingson, J Neuroonc, 2012
50 Advanced Neuroimaging Protocol for Clinical Trials Magnetic Resonance Imaging (MRI) Standard MR Techniques T2/FLAIR Edema Non-enhancing (infiltrating) tumor T2 Relaxometry Edema Diffusion MRI Cellularity, Proliferation, Invasion Dynamic Contrast-Enhanced (DCE) MRI Vascular Permeability Dynamic Susceptibility-Contrast (DSC) MRI Blood Volume, Blood Flow Contrast-Enhanced T1-Weighted Abnormal Vasculature Proliferative Tumor
51 Brain Tumor Contrast Enhancement Normal Vasculature Neovasculature
52 Brain Tumor Contrast Enhancement Normal Vasculature Neovasculature
53 Brain Tumor Contrast Enhancement Serial T1-Weighted Images Time
54 Dynamic Contrast Enhanced (DCE)-MRI Signal Intensity Time
55 Dynamic Contrast Enhanced (DCE)-MRI 2 Deg 5 Deg 10 Deg 15 Deg 30 Deg
56 Dynamic Contrast Enhanced (DCE)-MRI
57 Dynamic Contrast Enhanced (DCE)-MRI
58 Advanced Neuroimaging Protocol for Clinical Trials Magnetic Resonance Imaging (MRI) Standard MR Techniques T2/FLAIR Edema Non-enhancing (infiltrating) tumor T2 Relaxometry Edema Diffusion MRI Cellularity, Proliferation, Invasion Dynamic Contrast-Enhanced (DCE) MRI Vascular Permeability Dynamic Susceptibility-Contrast (DSC) MRI Blood Volume, Blood Flow Contrast-Enhanced T1-Weighted Abnormal Vasculature Proliferative Tumor
59 Dynamic Susceptibility Contrast (DSC)-MRI
60 Dynamic Susceptibility Contrast (DSC)-MRI
61 Dynamic Susceptibility Contrast (DSC)-MRI Signal Intensity Time
62 Dynamic Susceptibility Contrast (DSC)-MRI T1+C rcbv
63 Dynamic Susceptibility Contrast (DSC)-MRI T1+C rcbv
64 Dynamic Susceptibility Contrast (DSC)-MRI T1+C rcbv
65 Advanced Neuroimaging Protocol for Clinical Trials Magnetic Resonance Imaging (MRI) Standard MR Techniques T2/FLAIR Edema Non-enhancing (infiltrating) tumor T2 Relaxometry Edema Diffusion MRI Cellularity, Proliferation, Invasion Dynamic Contrast-Enhanced (DCE) MRI Vascular Permeability Dynamic Susceptibility-Contrast (DSC) MRI Blood Volume, Blood Flow Contrast-Enhanced T1-Weighted Abnormal Vasculature Proliferative Tumor
66 Standard MRI - Contrast Enhancement Pre-Contrast Post-Contrast
67 Standard MRI - Contrast Enhancement
68 Standard MRI - Contrast Enhancement
69 Positron Emission Tomography (PET)
70 Positron Emission Tomography (PET)
71 Positron Emission Tomography (PET) Parametric Response Maps Ellingson, PET Clinics, 2013 (In Press)
72 Positron Emission Tomography (PET) Parametric Response Maps Ellingson, PET Clinics, 2013 (In Press)
73 Positron Emission Tomography (PET) Parametric Response Maps Ellingson, PET Clinics, 2013 (In Press)
74 Positron Emission Tomography (PET) Parametric Response Maps Ellingson, PET Clinics, 2013 (In Press)
75 Advanced Neuroimaging Protocol for Neuro-Oncology Magnetic Resonance Imaging (MRI) T2/FLAIR T2 Relaxometry Diffusion MRI Edema & Infiltrating tumor Edema / Density Cellularity, Proliferation, Invasion Dynamic Contrast-Enhanced (DCE) MRI Vascular Permeability Dynamic Susceptibility-Contrast (DSC) MRI Blood Volume, Blood Flow Contrast-Enhanced T1-Weighted Abnormal Vasculature & Proliferative Tumor Positron Emission Tomography (PET) 18 F-FDG PET Glucose Metabolism 18 F-FLT PET DNA Synthesis / Proliferation 18 F-FDOPA PET Amino Acid Uptake/Transport/Metabolism
76 Challenges in a Multi-Center Clinical Trial Image Standardization
77 Challenges in a Multi-Center Clinical Trial Image Standardization
78 Challenges in a Multi-Center Clinical Trial Quality Control
79 Challenges in a Multi-Center Clinical Trial Scanner Variability
80 Benjamin M. Ellingson, Ph.D. Asst. Professor of Radiology, Biomedical Physics, and Bioengineering UCLA Brain Tumor Imaging Lab (BTIL) Dept. of Radiological Sciences David Geffen School of Medicine University of California - Los Angeles bellingson@mednet.ucla.edu (310) Westwood Blvd. Suite 615 Los Angeles, CA 90024
Clinical Trials for Adult Brain Tumors - the Imaging Perspective
Clinical Trials for Adult Brain Tumors - the Imaging Perspective Whitney B. Pope, M.D., Ph.D. Department of Radiology David Geffen School of Medicine at UCLA August 22, 2015 1 Disclosure of Financial Relationships
Contemporary Management of Glioblastoma
Contemporary Management of Glioblastoma Incidence Rates of Primary Brain Tumors Central Brain Tumor Registry of the United States, 1992-1997 100 Number of Cases per 100,000 Population 10 1 0.1 x I x I
Clinical ph, Hypoxia, and Vascular Architecture MR Imaging in Human Brain Tumors
Clinical ph, Hypoxia, and Vascular Architecture MR Imaging in Human Brain Tumors Benjamin M. Ellingson, Ph.D. Director, UCLA Brain Tumor Imaging Laboratory Co-Director, UCLA Center for Computer Vision
Benjamin M. Ellingson, Ph.D.
Simultaneous ph- and Oxygen-Weighted Metabolic Imaging of Brain Tumors using Multi-Echo Amine Chemical Exchange Saturation Transfer (CEST) Echo Planar Imaging Benjamin M. Ellingson, Ph.D. Associate Professor
Precision medicine for gliomas
Precision medicine for YAZMIN ODIA, MD MS LEAD PHYSICIAN OF MEDICAL NEURO-ONCOLOGY DISCLOSURES Novocure: Advisory Board for Optune in No other financial conflicts of interest Glioma OVERVIEW INFILTRATIVE,
Introduction to Modern Imaging Physics and Techniques used in Clinical Neurology
Introduction to Modern Imaging Physics and Techniques used in Clinical Neurology Benjamin M. Ellingson, Ph.D., M.S. Associate Professor of Radiology, Biomedical Physics, Bioengineering, and Psychiatry
It s s Always Something!
It s s Always Something! New Approaches in Brain Tumor Treatment Virginia Stark-Vance, M.D. When Something Is a Brain Tumor Brain tumors aren t rare: there are over 100,000/yr Most originate as other cancers
UNIVERSITY OF MEDICINE AND PHARMACY CRAIOVA PhD SCHOOL. PhD THESIS
UNIVERSITY OF MEDICINE AND PHARMACY CRAIOVA PhD SCHOOL PhD THESIS THE IMPORTANCE OF TUMOR ANGIOGENESIS IN CEREBRAL TUMOR DIAGNOSIS AND THERAPY ABSTRACT PhD COORDINATOR: Prof. univ. dr. DRICU Anica PhD
Off-Label Treatments. Clinical Trials for Recurrent GBM UCSF Radiation Oncology Course: Management of Recurrent Disease. Outline
Off-Label Treatments Clinical Trials for Recurrent GBM UCSF Radiation Oncology Course: Management of Recurrent Disease Jennifer Clarke, MD, MPH Assistant Professor Division of Neuro-Oncology Depts of Neurological
Durable Response Rate in High Grade Glioma: an Emerging Endpoint for Immunotherapeutics. Timothy Cloughesy, MD University of California, Los Angeles
Durable Response Rate in High Grade Glioma: an Emerging Endpoint for Immunotherapeutics Timothy Cloughesy, MD University of California, Los Angeles Disclosure 2 FDA Endpoints for the Approval of Cancer
MALIGNANT GLIOMAS: TREATMENT AND CHALLENGES
MALIGNANT GLIOMAS: TREATMENT AND CHALLENGES DISCLOSURE No conflicts of interest to disclose Patricia Bruns APRN, CNS Givens Brain Tumor Center Abbott Northwestern Hospital October 12, 2018 OBJECTIVES THEN
CNS Tumors: The Med Onc Perspective. Ronald J. Scheff, MD Associate Clinical Professor Weill Medical College of Cornell U.
CNS Tumors: The Med Onc Perspective Ronald J. Scheff, MD Associate Clinical Professor Weill Medical College of Cornell U. Disclosure Speakers Bureau, Merck Basic Oncology Concepts Tissue Diagnosis Stage
PRINCESS MARGARET CANCER CENTRE CLINICAL PRACTICE GUIDELINES
PRINCESS MARGARET CANCER CENTRE CLINICAL PRACTICE GUIDELINES CENTRAL NERVOUS SYSTEM ANAPLASTIC GLIOMAS CNS Site Group Anaplastic Gliomas Author: Dr. Norm Laperriere Date: February 20, 2018 1. INTRODUCTION
Glioblastoma: Adjuvant Treatment Abdulrazag Ajlan, MD, MSc, FRCSC, UCNS(D)
Glioblastoma: Adjuvant Treatment Abdulrazag Ajlan, MD, MSc, FRCSC, UCNS(D) *Neurosurgery Consultant, King Saud University, Riyadh, KSA *Adjunct Teaching Faculty, Neurosurgery, Stanford School Of Medicine,
Brain Tumors. What is a brain tumor?
Scan for mobile link. Brain Tumors A brain tumor is a collection of abnormal cells that grows in or around the brain. It poses a risk to the healthy brain by either invading or destroying normal brain
Predictive Biomarkers in GBM
Predictive Biomarkers in GBM C. David James, Ph.D. Professor & Associate Director, Brain Tumor Research Center Dept. Neurological Surgery and Helen Diller Comprehensive Cancer Center, University of California
Douglas Jolly Executive VP R&D Tocagen Inc.
REPLICATING RETROVIRUSES FOR MANIPULATION OF THE TUMOR IMMUNE ECOSYSTEM: PRECLINICAL AND CLINICAL OUTCOMES. Douglas Jolly Executive VP R&D Tocagen Inc. PEGS 2018 IT Track Boston May 1 2018 Outline Phase
Systemic Treatment. Third International Neuro-Oncology Course. 23 May 2014
Low-Grade Astrocytoma of the CNS: Systemic Treatment Third International Neuro-Oncology Course São Paulo, Brazil 23 May 2014 John de Groot, MD Associate Professor, Neuro-Oncology UT MD Anderson Cancer
Oncological Management of Brain Tumours. Anna Maria Shiarli SpR in Clinical Oncology 15 th July 2013
Oncological Management of Brain Tumours Anna Maria Shiarli SpR in Clinical Oncology 15 th July 2013 Outline General considerations of Primary Brain Tumours: epidemiology, pathology, presentation. Diagnosis
Antibody-Drug Conjugates in Glioblastoma Multiforme: Finding Ways Forward
Transcript Details This is a transcript of a continuing medical education (CME) activity accessible on the ReachMD network. Additional media formats for the activity and full activity details (including
Copyright. Tocagen Inc. Lead Product Candidate: Toca 511 & Toca FC Preclinical Overview
Lead Product Candidate: Toca 511 & Toca FC Preclinical Overview Toca 511, delivers CD prodrug activator gene selectively to cancer cells Regulatory genes Structural RRV genes CD gene Regulatory genes Toca
Index. neurosurgery.theclinics.com. Note: Page numbers of article titles are in boldface type.
Index Note: Page numbers of article titles are in boldface type. A A Complimentary Trial of an Immunotherapy Vaccine Against Tumor-specific EGFRvIII (ACTIVATE), 90 91 Active immunotherapy, 5 8, 96. See
Durable Responses Observed in IDH1 Wildtype and Mutant Recurrent High Grade Glioma with Toca 511 & Toca FC Treatment
Durable Responses Observed in IDH1 Wildtype and Mutant Recurrent High Grade Glioma with Toca 511 & Toca FC Treatment Cloughesy TF 1, Landolfi J 2, Vogelbaum MA 3, Ostertag D 4, Elder JB 5, Bloomfield S
Functional aspects of anatomical imaging techniques
Functional aspects of anatomical imaging techniques Nilendu Purandare Associate Professor & Consultant Radiologist Tata Memorial Centre Functional/metabolic/molecular imaging (radioisotope scanning) PET
Brain Tumor Treatment
Scan for mobile link. Brain Tumor Treatment Brain Tumors Overview A brain tumor is a group of abnormal cells that grows in or around the brain. Tumors can directly destroy healthy brain cells. They can
New Approaches in Brain Tumor Treatment. Virginia Stark-Vance, M.D.
New Approaches in Brain Tumor Treatment Virginia Stark-Vance, M.D. The Primary Brain Tumors es for PicturesMCD for 004.JPG 00 Meningioma 30% Glioblastoma 20% Astrocytoma 10% Nerve sheath 8% Pituitary 6%
Carmustine implants and Temozolomide for the treatment of newly diagnosed high grade glioma
National Institute for Health and Clinical Excellence Health Technology Appraisal Carmustine implants and Temozolomide for the treatment of newly diagnosed high grade glioma Personal statement Conventional
Clinical Management Protocol Chemotherapy [Glioblastoma Multiforme (CNS)] Protocol for Planning and Treatment
![Clinical Management Protocol Chemotherapy [Glioblastoma Multiforme (CNS)] Protocol for Planning and Treatment](/thumbs/87/96032554.jpg "Clinical Management Protocol Chemotherapy [Glioblastoma Multiforme (CNS)] Protocol for Planning and Treatment")
Protocol for Planning and Treatment The process to be followed when a course of chemotherapy is required to treat: GLIOBLASTOMA MULTIFORME (CNS) Patient information given at each stage following agreed
Corporate Medical Policy
Corporate Medical Policy Brachytherapy, Intracavitary Balloon Catheter for Brain Cancer File Name: Origination: Last CAP Review: Next CAP Review: Last Review: brachytherapy_intracavitary_balloon_catheter_for_brain_cancer
Glioblastoma: Current Treatment Approach 8/20/2018
Glioblastoma: Current Treatment Approach 8/20/2018 Overview What is Glioblastoma? How is it diagnosed How is it treated? Principles of Treatment Surgery, Radiation, Chemotherapy Current Standard of care
Laser Interstitial Thermal Therapy (LITT) in Neuro-Oncology. Tim Lucas, MD, PhD Neurosurgery
Laser Interstitial Thermal Therapy (LITT) in Neuro-Oncology Tim Lucas, MD, PhD Neurosurgery Timothy.Lucas@uphs.upenn.edu 2016 Laser Interstitial Thermal Therapy (LITT) in Neuro-Oncology Tim Lucas, MD,
1st Annual UCLA State-of-the-Art in Neuro-Oncology
1st Annual UCLA State-of-the-Art in Neuro-Oncology Part 2 Brain and Spine Metastases: A Comprehensive, Multidisciplinary Approach Saturday, December 12, 2015 NRB Auditorium Neuroscience Research Building
NAACR Treatment Webinar Quiz 1
NAACR Treatment Webinar Quiz 1 1. Which of the following would NOT be considered cancer-directed treatment? a. Hemicolectomy b. Incisional biopsy c. Whole breast radiation d. MRI e. All of the above f.
Brain Tumors: Radiologic Perspective
Brain Tumors: Radiologic Perspective Alberto Bizzi, M.D. Neuroradiology Humanitas Research Hospital Milan, Italy The job of the neuroradiologist in the work-up of brain tumors has quite changed in the
CNS SESSION 3/8/ th Multidisciplinary Management of Cancers: A Case based Approach
CNS SESSION Chair: Ruben Fragoso, MD/PhD UC Davis Fellow: Michael Cardenas, MD UC Davis Panel: Gordon Li, MD Stanford Seema Nagpal, MD Stanford Jennie Taylor, MD UCSF HPI: 46 yo right handed woman who
Durable Responses Observed in Recurrent High Grade Glioma (rhgg) with Toca 511 & Toca FC Treatment
Durable Responses Observed in Recurrent High Grade Glioma (rhgg) with Toca 511 & Toca FC Treatment Cloughesy TF 1, Landolfi J 2, Vogelbaum MA 3, Ostertag D 4, Elder JB 5, Bloomfield S 2, Carter B 6, Chen
CURRENT CONTROVERSIES IN THE MANAGEMENT OF HIGH GRADE GLIOMAS: AN INTERACTIVE CASE DISCUSSION *
CURRENT CONTROVERSIES IN THE MANAGEMENT OF HIGH GRADE GLIOMAS: AN INTERACTIVE CASE DISCUSSION * Alessandro Olivi, MD, Jaishri Blakeley, MD, and Allen K. Sills, MD, FACS ABSTRACT The management of glioma
Glioblastoma and CNS tumors
Glioblastoma and CNS tumors PRECEPTORSHIP PROGRAMME IMMUNO-ONCOLOGY Amsterdam, 27 May 2017 Patrick Roth Department of Neurology and Brain Tumor Center University Hospital Zurich Challenges in immunooncology
Management of Glioma: The Basics Glioma Update The clinical challenge. Glioma a malignant disease of the CNS
Management of Glioma: The Basics Glioma Update 3 oger Stupp, MD Department of Oncology & Cancer Center University Hospital Zurich, Switzerland (roger.stupp@usz.ch) Bern, 3. August 3 The clinical challenge
Bevacizumab: A Controversial Agent Against High-Grade Gliomas
Tumor Bevacizumab: A Controversial Agent Against High-Grade Gliomas Sussan Salas, MD 1, Miguel Guzman, MD 2, Kevin Judy, MD 1 1 Department of Neurological Surgery, Thomas Jefferson University, Philadelphia,
Magnetic Resonance Imaging for Prediction and Assessment of Treatment Response in Bevacizumab-Treated Recurrent Glioblastoma
Magnetic Resonance Imaging for Prediction and Assessment of Treatment Response in Bevacizumab-Treated Recurrent Glioblastoma The Harvard community has made this article openly available. Please share how
Protocol Abstract and Schema
Protocol Abstract and Schema Phase II study of Bevacizumab plus Irinotecan (Camptosar ) in Children with Recurrent, Progressive, or Refractory Malignant Gliomas, Diffuse/Intrinsic Brain Stem Gliomas, Medulloblastomas,
What Radiologists do?
Multimodality Imaging in Oncology 2018 March 5 th 9th Diagnostic Imaging in Oncology What Radiologists do? Chikako Suzuki, MD, PhD Department of Diagnostic Radiology, KS Solna Department of Molecular Medicine
10/16/2012. Neuro-Oncology The Beginnings. Neuro-Oncology The Beginnings. Primary Brain Tumors. Types of Primary Brain Tumors
Neuro Oncology From Old to New Maciej M Mrugala, MD, PhD, MPH Associate Professor Department of Neurology and Neurosurgery University of Washington Medical Center Neuro-Oncology The Beginnings Galen (129
Imaging for suspected glioma
Imaging for suspected glioma 1.1.1 Offer standard structural MRI (defined as T2 weighted, FLAIR, DWI series and T1 pre- and post-contrast volume) as the initial diagnostic test for suspected glioma, unless
Toca 511 (vocimagene amiretrorepvec) Retroviral replicating vector that carries a prodrug activator enzyme
TOCA 511 & TOCA FC: EVALUATION OF DURABLE RESPONSE RATE IN THE POST-RESECTION SETTING AND ASSOCIATION WITH SURVIVAL IN PATIENTS WITH RECURRENT HIGH GRADE GLIOMA Cloughesy TF 1, Landolfi J 2, Vogelbaum
THE EFFECTIVE OF BRAIN CANCER AND XAY BETWEEN THEORY AND IMPLEMENTATION. Mustafa Rashid Issa
THE EFFECTIVE OF BRAIN CANCER AND XAY BETWEEN THEORY AND IMPLEMENTATION Mustafa Rashid Issa ABSTRACT: Illustrate malignant tumors that form either in the brain or in the nerves originating in the brain.
Radioterapia no Tratamento dos Gliomas de Baixo Grau
Radioterapia no Tratamento dos Gliomas de Baixo Grau Dr. Luis Souhami University Montreal - Canada Low Grade Gliomas Relatively rare Heterogeneous, slow growing tumors WHO Classification Grade I Pilocytic
PRINCESS MARGARET CANCER CENTRE CLINICAL PRACTICE GUIDELINES
PRINCESS MARGARET CANCER CENTRE CLINICAL PRACTICE GUIDELINES CENTRAL NERVOUS SYSTEM LOW GRADE GLIOMAS CNS Site Group Low Grade Gliomas Author: Dr. Norm Laperriere 1. INTRODUCTION 3 2. PREVENTION 3 3. SCREENING
Imaging Cancer Treatment Complications in the Chest
Imaging Cancer Treatment Complications in the Chest Michelle S. Ginsberg, MD Objectives Imaging Cancer Treatment Complications in the Chest To understand the mechanisms of action of different classes of
Biologics Effects of Targeted Therapeutics
Report on the isbtc Mini-symposium on Biologics Effects of Targeted Therapeutics Michael B. Atkins, MD Beth Israel Deaconess Medical Center Louis Weiner, M.D. Fox Chase Cancer Center Report on the isbtc
Emerging contrasts at ultrahigh fields" A. Dean Sherry
Emerging contrasts at ultrahigh fields" A. Dean Sherry Advanced Imaging Research Center Department of Radiology UT Southwestern Medical Center Department of Chemistry & Biochemistry, UT Dallas ADVANCED
Colorectal Cancer Treatment
Scan for mobile link. Colorectal Cancer Treatment Colorectal cancer overview Colorectal cancer, also called large bowel cancer, is the term used to describe malignant tumors found in the colon and rectum.
Multiparametric imaging in oncology
Multiparametric imaging in oncology p1 T p2 p2 T T p3 p1 p3 T Marco Ravanelli Roberto Maroldi The goal of traditional imaging is high spatial and contrast resolution diagnosis, tumor extent treatment planning,
PI3-Kinase Signaling. Rational Incorporation of Novel Agents into Multimodality Therapy. PI3-kinase. PI3-kinase 5/2/2010
Rational Incorporation of Novel Agents into Multimodality Therapy I3-Kinase Signaling EGF IRS1 I3K EGFR I2 I3 TEN Rictor GßL AKT RAS40 Survival Raptor GßL Daphne Haas-Kogan UCSF Annual Course April 30-May
BY Mrs. K.SHAILAJA., M. PHARM., LECTURER DEPT OF PHARMACY PRACTICE, SRM COLLEGE OF PHARMACY
BY Mrs. K.SHAILAJA., M. PHARM., LECTURER DEPT OF PHARMACY PRACTICE, SRM COLLEGE OF PHARMACY Cancer is a group of more than 100 different diseases that are characterized by uncontrolled cellular growth,
BIT 120. Copy of Cancer/HIV Lecture
BIT 120 Copy of Cancer/HIV Lecture Cancer DEFINITION Any abnormal growth of cells that has malignant potential i.e.. Leukemia Uncontrolled mitosis in WBC Genetic disease caused by an accumulation of mutations
Pediatric Brain Tumors: Updates in Treatment and Care
Pediatric Brain Tumors: Updates in Treatment and Care Writer Classroom Rishi R. Lulla, MD MS Objectives Introduce the common pediatric brain tumors Discuss current treatment strategies for pediatric brain
LOW GRADE ASTROCYTOMAS
LOW GRADE ASTROCYTOMAS This article was provided to us by David Schiff, MD, Associate Professor of Neurology, Neurosurgery, and Medicine at University of Virginia, Charlottesville. We appreciate his generous
AMERICAN BRAIN TUMOR ASSOCIATION. Oligodendroglioma and Oligoastrocytoma
AMERICAN BRAIN TUMOR ASSOCIATION Oligodendroglioma and Oligoastrocytoma ACKNOWLEDGEMENTS ABOUT THE AMERICAN BRAIN TUMOR ASSOCIATION Founded in 1973, the American Brain Tumor Association (ABTA) was the
Chemotherapy in malignant brain tumors
Chemotherapy in malignant brain tumors Frank Zimmermann Institut für Radioonkologie Universitätsspital Basel Petersgraben 4 CH 4031 Basel zimmermannf@uhbs.ch Tumor types Neuro-epithelial tumors - Glioblastoma
Intravenous Delivery of Toca 511 in Patients With High Grade Glioma Results in Quantifiable Expression of Cytosine Deaminase in Tumor Tissue
Intravenous Delivery of Toca 511 in Patients With High Grade Glioma Results in Quantifiable Expression of Cytosine Deaminase in Tumor Tissue Tobias Walbert, 1 Daniela Bota, 2 Michael A Vogelbaum, 3 Steven
Glioblastoma and CNS tumors
Glioblastoma and CNS tumors PRECEPTORSHIP PROGRAMME IMMUNO-ONCOLOGY Amsterdam, 1 October 2016 Patrick Roth Department of Neurology and Brain Tumor Center University Hospital Zurich Immunology in the CNS
"The standard treatment for almost all cancers is surgical removal of the lump."
Cancer Treatment As continuous improvements in our knowledge and new and evolving methods of treatment are developed, pet owners and their veterinarians have more options available when cancer is diagnosed.
HALF. Who gets radiotherapy? Who gets radiotherapy? Half of all cancer patients get radiotherapy. By 1899 X rays were being used for cancer therapy
The Physical and Biological Basis of By 1899 X rays were being used for cancer therapy David J. Brenner, PhD, DSc Center for Radiological Research Department of Radiation Oncology Columbia University Medical
Corporate Medical Policy
Corporate Medical Policy Analysis of MGMT Promoter Methylation in Malignant Gliomas File Name: Origination: Last CAP Review: Next CAP Review: Last Review: analysis_of_mgmt_promoter_methylation_in_malignant_gliomas
Cilengitide (Impetreve) for glioblastoma multiforme. February 2012
Cilengitide (Impetreve) for glioblastoma multiforme February 2012 This technology summary is based on information available at the time of research and a limited literature search. It is not intended to
성균관대학교삼성창원병원신경외과학교실신경종양학 김영준. KNS-MT-03 (April 15, 2015)
성균관대학교삼성창원병원신경외과학교실신경종양학 김영준 INTRODUCTIONS Low grade gliomas (LGG) - heterogeneous group of tumors with astrocytic, oligodendroglial, ependymal, or mixed cellular histology - In adults diffuse, infiltrating
University of Colorado Cancer Center Brain Disease Site Schema
GBM FIRST LINE 18 0376/Kazia Phase 2a study (Part 1): A phase 2a study to evaluate the safety, pharmacokinetics and clinical activity of the PI3K/mTOR inhibitor GDC 0084 administered to patients with glioblastoma
21/03/2017. Disclosure. Practice Changing Articles in Neuro Oncology for 2016/17. Gliomas. Objectives. Gliomas. No conflicts to declare
Practice Changing Articles in Neuro Oncology for 2016/17 Disclosure No conflicts to declare Frances Cusano, BScPharm, ACPR April 21, 2017 Objectives Gliomas To describe the patient selection, methodology
Brain Schema March 2018
Breast Cancer w/brain Mets 14 2283 / Lilly Abemaciclib PO Breast Ca or Melanoma mets allowed Leptomeningeal mets excluded Want brain met tissue Melanoma w/brain Mets 14 2209 / Bristol Myers Squibb Nivolumab
National Horizon Scanning Centre. Bevacizumab (Avastin) for glioblastoma multiforme - relapsed. August 2008
Bevacizumab (Avastin) for glioblastoma multiforme - relapsed August 2008 This technology summary is based on information available at the time of research and a limited literature search. It is not intended
Targeted Medicine and Molecular Therapeutics. Angus McIntyre, M.D. Medical Oncologist, Addison Gilbert Hospital and Beverly Hospital October 6, 2009
Targeted Medicine and Molecular Therapeutics Angus McIntyre, M.D. Medical Oncologist, Addison Gilbert Hospital and Beverly Hospital October 6, 2009 Approaches to Cancer Prevention Screening and early diagnosis
Molecular Epidemiology. Financial Disclosures. Central Nervous System Tumors Neuro-Oncology Clinical Research
Financial Disclosures Update on clinical trials for malignant glioma Susan M. Chang MD, Director of Division of Neuro-Oncology Brain Tumor Research Center Department of Neurological Surgery UCSF Research
Treatment with Tumor-Treating Fields therapy and pulse dose bevacizumab in patients with bevacizumab-refractory recurrent glioblastoma: A case series.
School of Medicine Digital Commons@Becker Open Access Publications 2016 Treatment with Tumor-Treating Fields therapy and pulse dose bevacizumab in patients with bevacizumab-refractory recurrent glioblastoma:
Molecular Imaging in the Development of Cancer Therapeutics. Johannes Czernin
Molecular Imaging in the Development of Cancer Therapeutics Johannes Czernin Ahmanson Biological Imaging Division University of California Los Angeles Cancer Statistics Cancer Type 5-year Survival Rate
AMERICAN BRAIN TUMOR ASSOCIATION. Oligodendroglioma and Oligoastrocytoma
AMERICAN BRAIN TUMOR ASSOCIATION Oligodendroglioma and Oligoastrocytoma ACKNOWLEDGEMENTS ABOUT THE AMERICAN BRAIN TUMOR ASSOCIATION Founded in 1973, the American Brain Tumor Association (ABTA) was the
Corporate Medical Policy
Corporate Medical Policy File Name: Origination: Last CAP Review: Next CAP Review: Last Review: tumor_treatment_fields_therapy 9/2013 11/2017 11/2018 6/2018 Description of Procedure or Service Tumor-treatment
Current and Future Treatment Options for Glioblastoma
Current and Future Treatment Options for Glioblastoma Santosh Kesari, MD, PhD, FANA, FAAN Chair, Department of Translational Neurosciences and Neurotherapeutics John Wayne Cancer Institute & Pacific Neuroscience
Parisa Mirzadehgan, MPH, CCRP
Parisa Mirzadehgan, MPH, CCRP Approved therapy for a newly diagnosed GBM patient includes surgical resection radiation & temozolomide Upon recurrence there are few approved options surgical implantation
Neuro-Oncology Program
Neuro-Oncology Program The goals of the Neuro-oncology Committee are: 1) to improve duration and quality of life of brain tumor patients; 2) to assess disease and treatment-related effects on neurocognitive
Acute: Symptoms that start and worsen quickly but do not last over a long period of time.
Cancer Glossary Acute: Symptoms that start and worsen quickly but do not last over a long period of time. Adjuvant therapy: Treatment given after the main treatment. It usually refers to chemotherapy,
PET Guidance of Therapy for BNCT and in vivo B-10 imaging
INFN LNL Legnaro 17-19 Novembre 2009 Principles of Positron Emission Tomography and Radiopharmaceuticals PET Guidance of Therapy for BNCT and in vivo B-10 imaging Luca Menichetti, Ph.D C.N.R. Institute
Oligodendrogliomas & Oligoastrocytomas
Oligodendrogliomas & Oligoastrocytomas ABOUT THE AMERICAN BRAIN TUMOR ASSOCIATION Founded in 1973, the American Brain Tumor Association (ABTA) was the first national nonprofit organization dedicated solely
Goals for this Lecture. Case 1. Key Points MRI TECHNIQUES FOR DIFFERENTIAL DIAGNOSIS OF RECURRENT BRAIN LESIONS
MRI TECHNIQUES FOR DIFFERENTIAL DIAGNOSIS OF RECURRENT BRAIN LESIONS Goals for this Lecture 1. Review common appearances for recurrent tumor and treatment effects on conventional MRI 2. Discuss current
A Single Institution s Experience with Bevacizumab in Combination with Cytotoxic Chemotherapy in Progressive Malignant Glioma
REVIEW A Single Institution s Experience with Bevacizumab in Combination with Cytotoxic Chemotherapy in Progressive Malignant Glioma Tina Mayer, Jill Lacy and Joachim Baehring Medical Oncology, Yale University
Target Delineation in Gliomas. Prof PK Julka Department of Radiotherapy and Oncology AIIMS, New Delhi
Target Delineation in Gliomas Prof PK Julka Department of Radiotherapy and Oncology AIIMS, New Delhi 1 What is a glioma? A primary brain tumour that originated from a cell of the nervous system 2 Recommendations:
Corporate Medical Policy Tumor-Treatment Fields Therapy for Glioblastoma
Corporate Medical Policy Tumor-Treatment Fields Therapy for Glioblastoma File Name: Origination: Last CAP Review: Next CAP Review: Last Review: tumor-treatment_fields_therapy_for_glioblastoma 9/2013 11/2017
Animal chemotherapy Film radiotherapy Music cancer treatment
Cancer treatments Animal chemotherapy Film radiotherapy Music cancer treatment What are the main treatments? Hormone therapy Surgery Chemotherapy Radiotherapy Targeted anti-cancer therapy (immunotherapy)
New Biological and Immunological Therapies for Cancer
New Biological and Immunological Therapies for Cancer Sant P. Chawla, M.D., FRACP The Sarcoma Oncology Center, Santa Monica CA 90403 7 th International Conference on Drug Discovery &Therapy 1 Promising
CANCER TREATMENT. Sent from the Diagnostic Imaging Atlas Page 1 of 5
CANCER TREATMENT When cancer is diagnosed in a pet continuous improvements in our knowledge and new and evolving methods of treatment give options to owners and their veterinarians. These notes are provided
Mechanisms of Resistance to Antiangiogenic. Martin J. Edelman, MD University of Maryland Greenebaum Cancer Center Dresden, 2012
Mechanisms of Resistance to Antiangiogenic Agents Martin J. Edelman, MD University of Maryland Greenebaum Cancer Center Dresden, 2012 Angiogenesis: A fundamental attribute of cancer Premise of Anti-angiogenic
Concomitant (without adjuvant) temozolomide and radiation to treat glioblastoma: A retrospective study
Concomitant (without adjuvant) temozolomide and radiation to treat glioblastoma: A retrospective study T Sridhar 1, A Gore 1, I Boiangiu 1, D Machin 2, R P Symonds 3 1. Department of Oncology, Leicester
Breast Cancer Diagnosis, Treatment and Follow-up
Breast Cancer Diagnosis, Treatment and Follow-up What is breast cancer? Each of the body s organs, including the breast, is made up of many types of cells. Normally, healthy cells grow and divide to produce
The prognostic value of biomarkers in the evaluation of glioblastoma multiforme
Boston University OpenBU Theses & Dissertations http://open.bu.edu Boston University Theses & Dissertations 2017 The prognostic value of biomarkers in the evaluation of glioblastoma multiforme Gascon,
Drug-targeted therapies and Predictive Prognosis: Changing Role for the Pathologist
Drug-targeted therapies and Predictive Prognosis: Changing Role for the Pathologist Moderator: S. Terence Dunn, Ph.D. Associate Professor, Pathology Director, Molecular Pathology Laboratory University
Nuclear Medicine and PET. D. J. McMahon rev cewood
Nuclear Medicine and PET D. J. McMahon 150504 rev cewood 2018-02-15 Key Points Nuclear Medicine and PET: Imaging: Understand how Nuc Med & PET differ from Radiography & CT by the source of radiation. Be
HSV1716 Dose levels and Cohort size Dose level No of Patients HSV1716 Dosage 1* 3 to 6 1 ml of 1 x 10 5 infectious units HSV1716 per ml 2
Abstract and Schema: Description and Rationale: Pediatric high grade gliomas have a progressive initial course and high risk of relapse/ progression; making the 5-year overall survival rate 15-35% with
Incidence of Early Pseudo-progression in a Cohort of Malignant Glioma Patients Treated With Chemoirradiation With Temozolomide
405 Incidence of Early Pseudo-progression in a Cohort of Malignant Glioma Patients Treated With Chemoirradiation With Temozolomide Walter Taal, MD 1 Dieta Brandsma, MD, PhD 1 Hein G. de Bruin, MD, PhD